Bioventus (NSDQ:BVS) announced today that it received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece. Durham, North Carolina–based Bioventus said in a news release that the neXus ultrasonic surgical aspirator system — a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm — powers the BoneScalpel Access device. The neXus system combines all […]
Misonix
Bioventus closes acquisition of Misonix
Bioventus (NSDQ:BVS) announced today that it completed its previously announced acquisition of Misonix for an undisclosed amount. Durham, N.C.-based Bioventus said in a news release that Misonix, a developer of minimally invasive therapeutic ultrasonic technologies and regenerative medicine, has become a wholly-owned subsidiary following the acquisition for cash and common stock. Misonix’s offerings will add […]
Bioventus cleared to acquire Misonix
Bioventus (NSDQ:BVS) this week announced that its stockholders approved the merger and acquisition of Misonix for an undisclosed amount. The Durham, N.C.–based orthobiologics company’s stockholders approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix for the previously announced merger of the two companies. Through the deal, Misonix will become […]
CryoLife, Misonix sign distribution deal for NeoPatch
CryoLife this week said it signed a distribution agreement with Misonix where Misonix will have exclusive commercialization rights of NeoPatch. The NeoPatch, made by CryoLife, is a dehydrated and terminally sterilized chorioamniotic allograft that is made from human placental membrane. It is designed to treat a wide range of indications outside of cardiac and vascular […]
Department of Justice clears Misonix in China FPCA probe
Misonix (NSDQ:MSON) said last week that the U.S. Department of Justice has dropped its inquiry into the company following a probe of self-reported possible Foreign Corrupt Practices Act violations in China. The Justice Department action, detailed in an August 13, 2019, letter to the company, follows the Securities & Exchange Commission’s June 18, 2019, letter […]
Misonix lands CE Mark for Nexus ultrasonic platform
Misonix (NSDQ:MSON) said today that it has received the CE Mark for a new ultrasonic surgical platform. The Nexus platform combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single, fully integrated platform that was also designed to accommodate future solutions. The Nexus platform is driven by a new […]
SEC clears Misonix in China FCPA probe
Misonix (NSDQ:MSON) said today that the U.S. Securities & Exchange Commission cleared it after a probe of self-reported possible Foreign Corrupt Practices Act violations in China. The case dates back to the fall of 2016, when then-chairman & CEO Michael McManus Jr. stepped down just before Misonix delayed its annual report due to “deficiencies” in its internal […]
Misonix gains FDA clearance for ultrasonic surgical platform
Misonix (NSDQ:MSON) said today that it received FDA 510(k) clearance for a new ultrasonic surgical platform. The Nexus platform combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single, fully integrated platform that was also designed to accommodate future solutions. The Nexus platform is driven by a new […]
Misonix settles derivatives suit brought over Chinese FCPA case
Misonix (NSDQ:MSON) agreed to enact a six-year plan to reform its corporate governance and cover $500,000 worth of legal fees to settle a shareholders derivative complaint brought over alleged violations of the Foreign Corrupt Practices Act in China. The case dates back to the fall of 2016, when then-chairman & CEO Michael McManus Jr. stepped down […]
Misonix puts up $97m in stock for Solsys Medical
Misonix (NSDQ:MSON) said yesterday that it put $97 million in stock on the table for Solsys Medical, formerly Soluble Systems, and its TheraSkin regenerative wound dressing. The deal calls for Farmingdale, N.Y.-based Misonix to issue 5.7 million new shares to Solsys stockholders, which would leave MSON investors owning 64% of the new company and former Solsys […]
Cantel Medical taps ex-Cardinal Health COO Fotiades for CEO | Personnel Moves, March 5, 2019
Cantel Medical taps ex-Cardinal Health vet for CEO Cantel Medical (NYSE:CMD) said today that it named former Cardinal Health (NYSE:CAH) COO George Fotiades to be its new president & CEO, replacing Jorgen Hansen effective immediately. Fotiades will retain his seat on Cantel’s board, the Little Falls, N.J.-based company said. “On behalf of the board, I am very […]
